中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2014年
8期
804-807
,共4页
曾越灿%吴荣%迟峰%邢锐%蔡炜嵩%肖玉平%辛彦%王乃乾
曾越燦%吳榮%遲峰%邢銳%蔡煒嵩%肖玉平%辛彥%王迺乾
증월찬%오영%지봉%형예%채위숭%초옥평%신언%왕내건
盐酸埃克替尼%非小细胞肺癌%脑转移%靶向治疗
鹽痠埃剋替尼%非小細胞肺癌%腦轉移%靶嚮治療
염산애극체니%비소세포폐암%뇌전이%파향치료
Icotinib hydrochloride%Non-small cell lung cancer%Brain metastasis%Targeted therapy
目的 探讨盐酸埃克替尼治疗终末期(ECOGPS评分3、4分)非小细胞肺癌多发脑转移放疗后失败患者的效果.方法 终末期非小细胞肺癌多发脑转移放疗后失败患者33例,17例接受盐酸埃克替尼治疗,16例不接受盐酸埃克替尼治疗和其他放化疗.结果 2个月时,治疗组17例中9例为部分缓解,4例稳定,4例疾病进展,无完全缓解病例.对照组16例中4例稳定,其余12例疾病进展,无完全缓解病例.治疗组中位生存期为95 d,对照组中位生存期为60 d(P =0.007).结论 盐酸埃克替尼可延长终末期非小细胞肺癌多发脑转移放疗后失败患者的生存期.
目的 探討鹽痠埃剋替尼治療終末期(ECOGPS評分3、4分)非小細胞肺癌多髮腦轉移放療後失敗患者的效果.方法 終末期非小細胞肺癌多髮腦轉移放療後失敗患者33例,17例接受鹽痠埃剋替尼治療,16例不接受鹽痠埃剋替尼治療和其他放化療.結果 2箇月時,治療組17例中9例為部分緩解,4例穩定,4例疾病進展,無完全緩解病例.對照組16例中4例穩定,其餘12例疾病進展,無完全緩解病例.治療組中位生存期為95 d,對照組中位生存期為60 d(P =0.007).結論 鹽痠埃剋替尼可延長終末期非小細胞肺癌多髮腦轉移放療後失敗患者的生存期.
목적 탐토염산애극체니치료종말기(ECOGPS평분3、4분)비소세포폐암다발뇌전이방료후실패환자적효과.방법 종말기비소세포폐암다발뇌전이방료후실패환자33례,17례접수염산애극체니치료,16례불접수염산애극체니치료화기타방화료.결과 2개월시,치료조17례중9례위부분완해,4례은정,4례질병진전,무완전완해병례.대조조16례중4례은정,기여12례질병진전,무완전완해병례.치료조중위생존기위95 d,대조조중위생존기위60 d(P =0.007).결론 염산애극체니가연장종말기비소세포폐암다발뇌전이방료후실패환자적생존기.
Objective To investigate the efficacy of icotinib hydrochloride in the treatment for recurrent or progressive brain metastases after radiation in patients with end-stage (ECOG PS score 3-4 points) non-small cell lung cancer.Methods Thirty-three patients with recurrent or progressive brain metastases after radiation were divided into treatment group (n =17) and the control group (n =16).Patients in the treatment group were received icotinib hydrochloride treatment,in the control group did not receive icotinib hydrochloride treatment and any other chemoradiotherapy.Results There were 9 patients with partial remission,4 patients with stable disease,4 patients with disease progression,and no patients with complete remission in the treatment group after 2 months of treatment.There were 4 patients with stable disease,12 patients with disease progression,and no patients with complete remission in the control group.The median survival time was 95 d in the treatment group and 60 d in the control group(P =0.007).Conclusion Icotinib hydrochloride could improve the survival and disease control rate for recurrent or progressive brain metastases patients after radiation with end-stage non-small cell lung cancer.
